Central nervous system (CNS) injuries remain challenging to treat due to limited neurogenesis, inhibitory extracellular environments, and maladaptive neuroimmune responses. Psychedelic compounds, including classical serotonergic psychedelics, dissociative anesthetics, and empathogens, have re-emerged as mechanistically distinctive “psychoplastogens” capable of rapidly and persistently enhancing...
Psychedelics, particularly psilocybin, have garnered significant attention as potential therapeutic tools for treating substance use disorders (SUDs), such as those related to alcohol, nicotine, heroin (an opioid), or cocaine. Traditional treatments often fall short, leading to high relapse rates and an urgent need for innovative approaches. This article explores the emerging role of...
The surge of new psychoactive substances (NPS) poses significant public health challenges due to their unregulated status and diverse effects. However, existing in vivo models for evaluating their activities are limited. To address this gap, this study utilizes the model organism Caenorhabditis elegans (C. elegans) to evaluate the activity of amphetamine-type stimulants (ATS) and their analogs....
Exploring dying through the lens of psychedelic experiences offers transformative perspectives on the end-of-life process, potentially alleviating existential distress and enriching the quality of life for those nearing death. Their potential in palliative care, therapy, and spiritual exploration is increasingly recognized, promising to revolutionize end-of-life understanding and care.